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Abstract
Risk factors for non-Aspergillus mold infection (NAMI) and the impact on transplant outcome are 
poorly assessed in the current era of antifungal agents. Outcomes of 124 patients receiving 
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allogeneic HCT diagnosed with either mucormycosis [n=72] or fusariosis [n=52] between days 
0-365 after HCT are described and compared to a control cohort (n=11856). Patients with NAMI 
had more advanced disease [mucormycois 25%, fusariosis 23%, controls 18%; p = 0.004] and 
were more likely to have a KPS<90% at HCT [mucormycosis 42%, fusariosis 38%, controls 28%; 
p=0.048]. The 1-year survival after HCT was 22% (15–29%) for cases and was significantly 
inferior compared to controls [65%(64–65%); p < 0.001]. Survival from infection was similarly 
dismal regardless of mucormycosis [15% (8-25%)] and fusariosis [21% (11-33%)].
In multivariable analysis, NAMI was associated with a 6-fold higher risk of death (p<0.0001) 
regardless of the site or timing of infection. Risk factors for mucormycosis include preceding 
acute GVHD, prior aspergillus infection, and older age. For fusariosis, increased risks including 
receipt of cord blood, prior CMV infection, and transplant prior to May 2002. In conclusion, 
NAMI occurs infrequently, is associated with high mortality, and appears with similar frequency in 
the current antifungal era.
Introduction
Infections remain a significant cause of morbidity and mortality following both autologous 
and allogeneic hematopoietic cell transplantation (HCT). Registry data indicate that 13 - 
17% of patients receiving allogeneic HCT have infection as a primary cause of death(1). 
However, these data neither define the extensive morbidity nor the frequency of 
opportunistic infections and, they likely underestimate the full contribution of infection as a 
cause of death(2).
The etiology of infectious complications after transplantation is multifactorial and 
prevention of infection remains crucial to improve outcomes(3). Routine prophylaxis with 
fluconazole results in decreased Candida spp. infections compared to placebo(4); however 
since its institution, increasing Aspergillus spp. infections were noted(5). Since the approval 
of agents with anti-aspergillosis activity, case reports from individual institutions have 
suggested breakthrough infections of mucormycosis in patients receiving anti-aspergillus 
azoles or echinocandins(6-10). This was not seen in a randomized control trial comparing 
fluconazole to voriconazole for prophylaxis (11).
The frequency of pathologically or microbiologically confirmed post-transplant mold 
infections not due to Aspergillus spp. (non-Aspergillus mold infections, NAMI) fortunately 
remains rare. An analysis from the Transplant Associated Infection Surveillance Network 
(TRANSNET) identified 639 patients with invasive fungal infection out of 16,200 receiving 
hematopoietic cell transplant procedures between March 2001 and September 2005(7). The 
majority of these infections were due to Aspergillus spp. and Candida spp. with only 66 
reported cases of mucormycosis and 22 cases of fusariosis.
In order to better understand the impact of mucormycosis and fusariosis on transplant 
outcomes and to identify risk factors, potentially including antifungal prophylaxis, we 
designed and executed a retrospective observational study using the Center for International 
Blood and Marrow Transplant Research (CIBMTR) database.
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Methods
Patients
This analysis includes all patients receiving an allogeneic hematopoietic cell transplant for 
any indication and reported to the CIBMTR between 1995 and 2008. Patients received either 
conventional myeloablative or a reduced intensity/non-myeloablative conditioning from any 
donor source. Patients were considered cases if they were reported with either fusariosis 
(n=52) or mucormycosis (n = 72) (including Mucorales spp., Rhizopus spp., and 
Zygomycetes not otherwised specified) at any site occurring from day 0 up to one year 
following transplantation; additional NAMI were not included due to lack of sufficient 
numbers of cases reported of other organisms such as Scedosporium spp. All identified cases 
came from 66 transplant centers predominantly in North America (n=50) with additional 
centers in Europe (n=5), Asia (n=2), Australia/New Zealand (n=4), Middle East/Africa 
(n=2) and Central/South America (n=3). To minimize ascertainment bias since the CIBMTR 
does not collect data using EORTC-MSG criteria, a comparison control cohort (n=11,856) 
included all patients from the same centers as cases who met all other inclusion criteria but 
did not have a NAMI reported in the first year after transplant(12). This restriction 
potentially minimizes prophylaxis, diagnostic, and treatment biases as well.
Data Sources
Data were obtained from the CIBMTR, a research affiliate of the International Bone Marrow 
Transplant Registry, Autologous Blood and Marrow Transplant Registry, and the National 
Marrow Donor Program (NMDP) established in 2004. It comprises a voluntary working 
group of more than 450 transplantation centers worldwide that contribute data on 
consecutive allogeneic and autologous HCT procedures to a statistical center at the Medical 
College of Wisconsin in Milwaukee and the NMDP Coordinating Center in Minneapolis. 
Participating centers report longitudinal data on all transplants and compliance is monitored 
by on-site audits. Transplant essential data, collected for consented patients participating in 
CIBMTR data collection, include demographic, disease type and stage, survival, relapse, 
graft type, the presence of GVHD, and cause of death data. A subset of CIBMTR 
participants are selected for comprehensive research level data collection by weighted 
randomization. Observational studies conducted by the CIBMTR are performed in 
compliance with all applicable federal regulations pertaining to the protection of human 
research participants. Protected health information used in the performance of such research 
is collected and maintained in CIBMTR's capacity as a Public Health Authority under the 
Health Insurance Portability and Accountability Act Privacy Rule. Studies conducted by the 
CIBMTR are performed under guidance and review of the Institutional Review Board of the 
National Marrow Donor Program.
Definitions and Endpoints
Conditioning intensity was defined as myeloablative or non-myeloablative using criteria 
defined by CIBMTR(13). Performance status at the time of HCT was defined according to 
the Karnofsky scale for patients 16 and older, or the Lansky scale for those younger than 16 
years. Leukemia disease stage for patients with AML, ALL, and CML was categorized as 
early [CR1, CP1], intermediate [≥ CR2/CP2, Rel 1, or AP], or advanced [all other stages]. 
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HLA-match grade categories for unrelated donors were categorized as previously published 
(14). Infection data are reported by centers with an organism code, a date of onset, and a site 
of infection. Sites of infection are reported as disseminated if the organism is found in 3 or 
more non-contiguous sites. Data regarding method of diagnosis, severity of infection, and 
treatment are not captured.
Outcomes of interest included overall survival (OS) from the time of transplant, OS from the 
time of NAMI, and risk factors for each infection. Infections with cytomegalovirus (CMV) 
and aspergillosis were assessed for both cases and controls. Acute graft versus host disease 
(GVHD) was defined as the occurrence of grade II-IV skin, gastrointestinal, and/or liver 
abnormalities fulfilling the Glucksberg criteria of acute GVHD (15). Chronic GVHD was 
defined using the NIH consensus criteria (16).
Statistical Analysis
Descriptive statistics for patient, disease, and transplant-related factors were compared using 
Chi-squared analysis or Mann-Whitney testing as appropriate. A Kaplan Meyer analysis for 
OS from the time of transplant was determined. Cox modeling was employed to determine 
the effect of NAMI on OS adjusted for factors at the time of transplant as well as the time 
dependent co-variates of acute and chronic GVHD. Cox models also determined the effect 
of infection site and the time of infection onset following transplant on OS.
To account for multiple infectious episodes occurring in a single patient and adjusted for a 
period of time at risk, infection density was determined (17). This was calculated 
specifically for CMV infection and aspergillosis for the first year after transplant. A 
recurrent infection required a period of 60 days without evidence of CMV or 90 days 
without evidence of aspergillosis following an initial infectious event (18).
Estimation of OS from the time of NAMI was determined within the infection cohort. 
Additionally, a Cox model was used to identify risk factors for the diagnosis of 
mucormycosis and fusariosis. Variables included age; stem cell source; disease and disease 
status at transplant; co-morbid conditions of endocrine, pulmonary, and/or autoimmune 
disease; Karnofsky performance status; acute GVHD before infection; chronic GVHD 
before infection; CMV reactivation before NAMI; aspergillosis before NAMI; and year of 
transplant prior to or after May 2002 as a surrogate for antifungal prophylaxis. These 
variables had a p-value ≤0.1 in univariate analysis between cases and controls or were 
incorporated as time dependent variables that may impact the likelihood of NAMI.
Median follow-up of the survivors was 61 months (range, 13 – 132 months) for cases and 62 
months (range, 1 – 186 months) for controls.
Results
Patients
Key characteristics of patients with mucormycosis, fusariosis, and controls are shown in 
Table 1. Patients with mucormycosis were older [median, 47 years (range, 3-68 years)] 
compared to either the cases with fusariosis or the controls [fusariosis: 32 years (range, 1–63 
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years); controls: 34 years (<1–79 years); p <0.001]. Patients in the control cohort were more 
likely to have a KPS ≥ 90% at the time of transplant [mucormycosis: 56%, fusariosis: 60%; 
controls: 68%; p = 0.048]. Although there was no difference in the disease indication for 
transplant, cases were less likely to have early stage leukemia compared to controls 
[mucormycosis: 38%; fusariosis: 42%; controls: 53%; p = 0.004]. The frequency of certain 
co-morbid conditions including pulmonary disease, endocrine diseases, and autoimmune 
disease was assessed as these conditions may be associated with increased risk of infection. 
There was no difference in the frequency of these comorbidities although pulmonary disease 
was slightly more common for patients with mucormycosis and autoimmune diseases for 
patients with fusariosis.
Transplant related variables, such as donor/recipient gender match, CMV serostatus match, 
and HLA match were similar between cases and controls (Table 1). Additionally, the use of 
myeloablative conditioning was similar between the groups [mucormycosis: n = 46 (64%); 
fusariosis: n = 39 (75%), controls: n = 8075 (68%), p = 0.43].
Infection
The rate of NAMI was 10.35 cases per 1000 patients transplanted (mucormycosis: 
6.01/1000; fusariosis: 4.34/1000) in these 66 centers. In comparison, the rate of Aspergillus 
occurring in the first year after transplant was 45.9 cases per 1000 patients transplanted. 
When analyzed by stem cell source, there were 7.71 cases per 1000 bone marrow grafts, 
11.93 cases per 1000 peripheral blood stem cell grafts, and 15.24 cases per 1000 umbilical 
cord blood grafts (p = 0.02). There was also a slightly higher rate of NAMI in recipients of 
adult unrelated donor grafts (11.53/1000 transplants) compared to patients receiving related 
donor allografts (9.31/1000 transplants, p = 0.19).
Information on systemic antifungal prophylaxis is shown in Table 2. The antifungal 
prophylaxis did not differ between the groups (p = 0.549). No systemic antifungal 
prophylaxis was administered to 13 (18%) mucormycosis cases, 6 (12%) fusariosis cases, 
and 2000 (17%) controls. The predominant antifungal agent used was fluconazole 
[mucormycosis: 40%; fusariosis: 54%; controls: 53%] and there was no difference in the use 
of any azole (p=0.148). Information on dosing and duration of antifungal prophylaxis was 
not available.
The median time from transplant to infection onset was 48 days (range, 1-363) for all NAMI 
(mucormycosis: 75 days (1-360); fusarium: 28 days (0-363). This was earlier than the onset 
for Aspergillus infections, which occurred at a median of 96 days (range, 14-230). The 
majority of NAMI occurred in the first 100 days post-transplant with only 35 (28%) cases 
occurring between 3 months and one year post-transplant. In the first 3 months post-
transplant, infections occurred primarily between day 0 - 30 [n = 49 (40%)] with a similar 
distribution occurring from day 31 – 60 [n=18 (15%)] and day 61 – 100 [n = 22 (18%)]. 
Only 14 (11%) cases experienced relapse of the underlying hematologic malignancy prior to 
the diagnosis of NAMI occurring at a median of 2.3 months.
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As expected, sinus/respiratory was the most common site of infection reported occurring in 
55 (44%) cases. The remaining cases occurred in the blood/marrow (14%), GI tract (14%), 
skin only (6%), CNS (2%), and musculoskeletal system (<1%). Five (4%) patients were 
reported with disseminated infection, and 18 patients had no site of infection reported.
Since patients are at risk for multiple infections during the first year after HCT, we 
determined the infection density for CMV and aspergillosis and compared between the cases 
and controls. There was no difference in the rate of CMV infection between cases and 
controls [cases: 0.57 per patient vs controls: 0.29 per patient; p = 0.55]; however, cases had a 
4-fold higher rate of aspergillosis compared to controls [cases: 0.29 per patient vs controls: 
0.07 per patient; p <0.001] The number of NAMI patients with aspergillosis was small (n = 
14) and only 7 patients were diagnosed prior to or concomitant with the NAMI diagnosis.
In multivariable analyses (Tables 3, 4), prior aspergillosis was the greatest risk factor for 
development of mucormycosis in the first year after transplant. Other risk factors included 
age > 50 years and prior acute GVHD. The risks for fusariosis included receipt of umbilical 
cord blood, prior CMV infection, and transplant between 1995 and April 2002. Notably, 
year of transplant did not increase the risk of mucormycosis. Other factors not increasing the 
risk for either mucormycosis or fusariosis include KPS, prior chronic GVHD, disease and 
disease status at transplant, nor co-morbid conditions of prior pulmonary, endocrine, or 
autoimmune disease.
Survival
The overall survival from transplant was significantly inferior for patients developing a 
NAMI with only 22% (95% confidence interval (CI): 15 – 29%) of cases alive at 1 year 
compared to 65% (95% CI: 64 – 65%) of controls [p <0.0001] (Figure 1A). For patients 
with NAMI, most died within 30 days of the diagnosis and the probability of survival at 100 
days following NAMI was only 27% (95% CI: 20 – 35%) (Figure 1B). The type of NAMI 
did not change the poor outcome [100 day OS, mucormycosis: 29% (95% CI: 19-40%); 
fusariosis: 25% (14-37%)], and, therefore, fusariosis and mucormycosis were combined for 
the multivariable analysis of OS.
In multivariable analysis, patients with a NAMI had a 6-fold greater risk of death compared 
to the controls and this was not impacted by the site of the infection [bloodstream: 6.41 
(95% CI: 3.69 – 11.13) vs. GI: 6.34 (95% CI: 4.67 – 8.59) vs. respiratory: 6.43 (95% CI: 
3.74 – 11.23) vs other site: 5.30 (95% CI: 3.59 – 7.81)]. Infections diagnosed beyond day 
100 post-transplant [11.78 (95% CI: 7.76 – 17.87)] were associated with a higher risk of 
death compared to infections in the first 100 days [0 – 30 days: 5.67 (95% CI: 4.14 – 7.77), 
p = 0.006; 31 – 60 days: 7.67 (95% CI: 4.67 – 12.60), p = 0.19; 61 – 100 days: 4.36: (95% 
CI: 2.65 – 7.18), p = 0.002]. Other factors increasing the risk of death were as expected and 
included acute GvHD grade 2 – 4, advanced leukemia, older age, KPS <90%, greater degree 
of HLA-mismatch, and transplant between 1995 – April 2002. GvHD prophylaxis with T-
cell depletion methods or methotrexate without calcineurin inhibitors also resulted in 
inferior survival. Infection was reported as the primary cause of death in 51% of patients 
with NAMI and only 19% of controls (Table 5).
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Discussion
Our data represent a large cohort of patients receiving allogeneic HCT from 66 centers 
reporting to the CIBMTR. Within a cohort of 11,980 patients, only 124 (1%) developed an 
NAMI with either mucormycosis or fusariosis between the time of stem cell infusion and 
one year post transplant. However for that 1% of patients, outcomes were dismal with only 
22% of patients alive one year after transplant and only 27% of patients alive 3 months after 
the diagnosis of NAMI. Risk factors increasing the likelihood of mucormycosis included 
prior GVHD, older age, and prior Aspergillus spp. infection. Notably, there was no 
difference based on year of transplant preceding or following May 2002 as a surrogate for 
potential increased use of voriconazole in the risk of developing mucormycosis. The risks 
were different for fusariosis and included use of umbilical cord blood, prior CMV infection, 
and earlier transplant period.
Neutropenia and impaired cell-mediated immunity are known risk factors for the 
development of invasive fungal infections. Other risk factors include iron overload, poorly 
controlled diabetes mellitus, and prolonged use of corticosteroids (19-21). Many of these 
factors are clearly present in an allogeneic HCT population. However, in general, these risk 
factor analyses have focused on all invasive fungal infections which are generally 
predominated by aspergillosis and candida infections (5, 19, 20). In recent years, single 
center publications document breakthrough mucormycosis in patients receiving anti-
aspergillosis prophylaxis (6, 8, 22). Large multicenter randomized controlled trials did not 
support this finding (11, 23). Our data also dispute evidence of increasing NAMI in the 
recent antifungal era. In fact, the overall incidence and rate per 1000 allogeneic transplants 
from our analysis is similar to that reported by Garcia-Vidal and colleagues for patients 
transplanted prior to 2003 in two centers, a single center publication for patients transplanted 
from 1985 through 1989 by Marr et al., and the more recent TRANSNET prospective 
surveillance for patients receiving either autologous or allogeneic transplant at 22 centers 
between March 2001 and March 2006 (5, 7, 20). Consequently, it does not appear that the 
use of voriconazole increases the risk of mucormycosis; however, further analyses in which 
larger numbers of patients are exposed to voriconazole are warranted to confirm this finding. 
Conversely, it appears that the FDA approval of voriconazole corresponds with a decreased 
risk of fusariosis in our population although voriconazole prophylaxis was rare in our study. 
Data suggests improved survival in patients with disseminated fusariosis treated with 
voriconazole.(24) It is possible that the decreased risk of fusariosis after May 2002 may 
reflect an earlier transition to voriconazole for empiric therapy in a neutropenic patient; 
unfortunately, we do not have treatment data to confirm this hypothesis.
Despite the small number of patients diagnosed with aspergillosis either preceding or 
concomitant with the NAMI diagnosis, aspergillosis was associated with more than a 4-fold 
increased risk of mucormycosis in multivariable analysis. As previously noted, risk factors 
for invasive fungal infections are likely similar regardless of the causative organism; 
therefore, this risk factor may simply serve as a surrogate for extensive defects in both innate 
and adoptive immunity resulting in increased risk of any opportunistic infection. 
Alternatively, it is possible that patients were mis-diagnosed or mis-reported with 
aspergillosis in the setting of a mold infection. However, this finding may also explain the 
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suggested breakthrough of mucormycosis with the use of voriconazole since patients may be 
surviving the aspergillosis due to use of voriconazole and ultimately live long enough to 
manifest an alternative NAMI (6, 8, 22).
As expected, survival following NAMI is quite poor. Unfortunately, and more concerning, 
this does not appear to have improved in the era of newer antifungal agents. Based on our 
analysis, the one-year survival following infection with mucormycosis is approximately 
15%. For fusariosis, 1 year survival following infection is approximately 21%. These data do 
not differ from outcomes published in 2002 for patients receiving HCT from 1985 through 
1999 (5). Until better therapies are identified, our ability to improve outcomes from NAMI 
will require prevention of exposure, continued improvement in diagnostic techniques, and 
modification of risk factors in the allogeneic HCT population.
Our study has clear limitations due to its observational cohort design. A major limitation is 
the reported data for antifungal prophylaxis. Notably, 15% of cases and 17% of controls 
were reported to receive no antifungal prophylaxis. Additionally, several patients were 
reported to receive more than one antifungal agent as “prophylaxis”. Data are lacking 
regarding timing and duration of antifungal prophylaxis as well as length of empiric 
antifungal therapy and changes in therapy that occurred during the transplant course. 
Furthermore, we have no data regarding duration of corticosteroid use in either the cases or 
controls. Finally, the infections are reported by organism, date of onset, and site of infection 
is requested, but the CIBMTR does not collect diagnostic criteria to determine “proven” or 
“probable” by EORTC-MSG criteria; therefore, there is the possibility of both under- and 
over-reporting which could affect a risk factor analysis. (12) We have no information on the 
clinical symptoms or severity of the infection; therefore, it is possible that some cases 
represent colonization or contaminants rather than an invasive infection. We attempted to 
account for this by limiting our control cohort to those transplant centers that had cases 
making the assumption that transplant centers generally employ similar prophylaxis, 
treatment paradigms, and diagnostic and data reporting criteria across the transplant patient 
population.
Our data demonstrate that NAMI occur infrequently but are most common early after HCT. 
This observation is not surprising since most patients have multiple risk factors including 
impaired cellular immunity as well as neutropenia during this time (21). However, those 
NAMI which occurred beyond 100 days post-transplant were twice as likely to be fatal as 
the patients diagnosed during the first 30 days post-transplant. This may be due to relapse of 
the underlying hematologic malignancy preceding the infection. Alternatively, this outcome 
may be due to lack of awareness of ongoing risk and exposures to these ubiquitous microbes 
as patients are commonly seen less frequently at the transplant centers later in the transplant 
course. Education of patients and referring physicians about the on-going risk of NAMI and 
adjustments in prophylaxis may be necessary to decrease these infections (25).
In summary, NAMI remain uncommon but highly fatal infections following allogeneic HCT. 
Prolonged vigilance for the development of NAMI is required, particularly after 
development of acute GVHD or other opportunistic infections and may require novel 
antifungal prophylaxis schedules. Detailed accurate information on prophylaxis and 
Riches et al. Page 8
Bone Marrow Transplant. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
antifungal therapy is required to better understand the implications of these agents on the 
development and outcome of NAMI. The CIBMTR is now collecting detailed information 
on all research patients reported with invasive mold infections.
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1A. 
Overall survival from the time of transplantation for patients with NAMI compared to the 
control population from the same centers.
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1B. 
Overall survival from the time of AMI. Represented are all patients (---), patients with 
mucormycosis ( ), and with fusariosis ( ).
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Table 1
Pre-transplant characteristics of patients with mucormycosis, fusariosis, and controls
Variable N (%) Mucormycosis (n =72) Fusariosis (n =52) Controls (n = 11856) p-value
Age, yrs [median (range)] 47 (3 – 68) 32 (1 – 63) 34 (<1 – 79) <0.001
Gender, male 47 (65%) 31 (60%) 6924 (58%) 0.491
KPS at HCT 0.048
    ≥ 90% 40(56%) 31 (60%) 8049 (68%)
    < 90% 30 (42%) 20 (38%) 3330 (28%)
    unknown 2 ( 3%) 1 ( 2%) 477 ( 4%)
Co-morbid illness at HCT
    Pulmonary 11 (15%) 5 (10%) 1059 (9%) 0.183
    Endocrine 9 (13%) 5 (10%) 888 (7%) 0.353
    Autoimmune 1 ( 1%) 4 ( 8%) 266 (2%) 0.060
Disease 0.233
    AML/ALL/MDS 42 (58%) 24 (46%) 6216 (52%)
    NHL/HL 8 (11%) 7 (13%) 1088 ( 9%)
    CML 7 (10%) 4 ( 8%) 1511 (13%)
    CLL 5 ( 7%) 1 ( 2%) 375 ( 3%)
    SAA 4 ( 6%) 5 (10%) 926 ( 8%)
    Plasma cell disorders 0 3 ( 6%) 207 ( 2%)
    Other diseases 6 ( 8%) 8 (15%) 1455 (12%)
Leukemia Disease Stage 0.004
    Early 15 (38%) 11 (42%) 3500 (53%)
    Intermediate 11 (28%) 9 (35%) 1800 (27%)
    Advanced 10 (25%) 6 (23%) 1162 (18%)
    Missing 4 (10%) 0 121 ( 2%)
Donor/Recipient Gender Match 0.293
    Female/Male 21 (29%) 17 (33%) 2805 (24%)
    Female/Female 8 (11%) 9 (17%) 2147 (18%)
    Male/Female 13 (18%) 9 (17%) 2424 (20%)
    Male/Male 20 (28%) 13 (25%) 3610 (30%)
    UNK/Male 6 ( 8%) 1 ( 2%) 511 ( 4%)
    UNK/Female 4 ( 6%) 3 ( 6%) 359 ( 3%)
Donor/Recipient CMV status 0.571
    Positive/Positive 29 (40%) 16 (31%) 4289 (36%)
    Positive/Negative 4 ( 6%) 5 (10%) 1189 (10%)
    Negative/Positive 12 (17%) 14 (27%) 2395 (20%)
    Negative/Negative 18 (25%) 9 (17%) 2799 (24%)
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Variable N (%) Mucormycosis (n =72) Fusariosis (n =52) Controls (n = 11856) p-value
    Missing 9 (13%) 8 (15%) 1184 (10%)
Donor/Recipient HLA match 0.229
    HLA-identical siblings 42 (58%) 26 (50%) 7608 (64%)
    Other related 4 ( 6%) 5 (10%) 591 ( 5%)
    Well-matched unrelated 12 (17%) 4 ( 8%) 1439 (12%)
    Partially matched unrelated 3 ( 4%) 6 (12%) 708 ( 6%)
    Mismatched unrelated 2 ( 3%) 1 ( 2%) 190 ( 2%)
    Umbilical cord blood 9 (13%) 10 (19%) 1228 (10%)
Stem cell source 0.037
    Bone marrow 23 (32%) 19 (37%) 5408 (46%)
    Peripheral blood 40 (56%) 23 (44%) 5220 (44%)
    Umbilical cord blood 9 (13%) 10 (19%) 1228 (10%)
GvHD Prophylaxis 0.300
    T-cell depletion 6 ( 8%) 2 ( 4%) 475 ( 4%)
    Tacrolimus ± Other 24 (33%) 14 (27%) 3032 (26%)
    Cyclosporine ± Other 39 (54%) 35 (67%) 7887 (66%)
    Other 3 ( 4%) 1 ( 2%) 462 ( 4%)
Year of Transplant 0.044
    1995 – April 2002 28 (39%) 32 (62%) 5632 (48%)
    May 2002 – 2008 44 (61%) 20 (38%) 6224 (52%)
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Table 2
Frequency of systemic antifungal prophylaxis administered.
Antifungal Prophylaxis N (%) Mucormycosis (n = 72) Fusariosis (n = 52) Controls (n =11856) p-value
0.549
Azoles 0.148
    Fluconazole 29 (40%) 28 (54%) 6264 (53%)
    Voriconazole 8 (11%) 1 ( 2%) 683 ( 6%)
    Itraconazole 5 ( 7%) 2 ( 4%) 512 ( 4%)
    Posaconazole 1 ( 1%) 0 74 (<1%)
Amphotericin 14 (19%) 13 (25%) 1782 (15%)
Echinocandin 1 ( 1%) 0 158 ( 1%)
Other agent (including clinical trial) 1 ( 1%) 2 ( 4%) 319 ( 3%)
None 13 (18%) 6 (12%) 2000 (17%)
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Table 3
Multivariable analysis for risk factors for development of mucormycosis in the first year after transplant
Variable RR for mucormycosis (95% confidence interval) p-value
Acute GvHD grade II – IV 0.027
    No 1.00
    Yes 1.78 (1.07 – 2.98)
Prior Aspergillus infection 0.0007
    No 1.00
    Yes 4.91 (1.96 – 12.28)
Age 0.0006
    ≤ 50 years 1.00
    > 50 years 2.28 (1.42-3.65)
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Table 4
Multivariable analysis for risk factors for development of fusariosis in the first year after transplant
Variable RR for fusariosis (95% confidence interval) p-value
Prior CMV infection 0.013
    No 1.00
    Yes 2.72 (1.24 – 5.97)
Stem cell source 0.017
    Bone marrow 1.00
    Peripheral blood 1.61 (0.86 – 3.02) 0.136
    Umbilical cord blood 3.11 (1.14 – 6.81)* 0.004
Year of Transplant 0.009
    1995 – April 2002 1.00
    May 2002 – 2008 0.46 (0.26 – 0.82)
*
Peripheral blood vs Umbilical Cord blood: 0.52 (0.25 – 1.09), p = 0.082
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Table 5
Primary causes of death (COD) reported for deceased patients in this analysis
Primary COD Mucormycosis (n =62) Fusariosis (n =46) Controls (n =5947)
Infection 32 (52%) 23 (50%) 1141 (19%)
Relapse 10 (16%) 5 (11%) 2227 (37%)
GVHD 6 (10%) 5 (11%) 690 (12%)
Organ failure 11 (18%) 6 (13%) 877 (15%)
Other 3 ( 5%) 7 (15%) 898 (15%)
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